{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T22:49:53Z","timestamp":1792018193105,"version":"4.4.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Transgender and nonbinary (TGNB) individuals comprise 0.5% to 0.6% of the U.S. population and face significant healthcare disparities, yet little is known about inflammatory bowel disease (IBD) in this group. We aimed to characterize IBD prevalence, comorbidities, healthcare utilization, and the impact of hormone replacement therapy (HRT) in TGNB individuals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using TriNetX, we analyzed (1) IBD prevalence among TGNB adults, (2) comparisons of IBD patients who are and who are not TGNB, and (3) comparisons of TGNB IBD patients with and without HRT. Outcomes included demographics, comorbidities, laboratory markers, healthcare encounters, IBD treatment, and cardiovascular and thrombotic events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 111\u2009227 TGNB patients, prevalence of Crohn\u2019s disease and ulcerative colitis was 0.508% and 0.448%, respectively, increasing with age. TGNB patients were younger (32.5\u2009years of age vs 46.9 years of age; P\u2009&amp;lt; .001), exhibited higher rates of gastrointestinal and psychiatric comorbidities, and had more outpatient, emergency, and hospital visits, yet they underwent fewer endoscopies (25.7% vs 30.7% risk; P\u2009= .011) and were less likely to receive targeted IBD therapy than cisgender patients. Patients with HRT had more outpatient encounters (66.7% vs 58.2%; P\u2009= .010) and were more likely to use therapies like mesalamine (12.4% vs 7.6%; P\u2009= .021) than those without HRT. There were no significant differences in laboratory markers or thrombotic or cardiovascular events in these analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>TGNB IBD patients experience greater gastrointestinal and psychiatric comorbidities and receive fewer interventions overall despite greater healthcare contact. HRT was not associated with worsening disease or complications. These findings highlight critical disparities and the need for further research in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ibd\/izaf266","type":"journal-article","created":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T11:57:13Z","timestamp":1761393433000},"page":"643-649","source":"Crossref","is-referenced-by-count":2,"title":["Characterizing Healthcare Disparities, Utilization, and Trends of Inflammatory Bowel Disease in Transgender and Nonbinary Patients: A Population-Based Study"],"prefix":"10.1093","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-6395-5709","authenticated-orcid":false,"given":"Andrew","family":"Suchan","sequence":"first","affiliation":[{"name":"Division of Internal Medicine, Department of Medicine, Johns Hopkins University School of Medicine , Baltimore, MD,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1294-8790","authenticated-orcid":false,"given":"Lara","family":"Chaaban","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Johns Hopkins University School of Medicine , Baltimore, MD,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7874-6314","authenticated-orcid":false,"given":"Lynn","family":"Kobeissi","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Johns Hopkins University School of Medicine , Baltimore, MD,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4037-8740","authenticated-orcid":false,"given":"Bashar A","family":"Hassan","sequence":"additional","affiliation":[{"name":"Department of Plastic and Reconstructive Surgery, Center for Transgender and Gender Expansive Health, The Johns Hopkins University School of Medicine , Baltimore, MD,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2867-4413","authenticated-orcid":false,"given":"Fan","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Plastic and Reconstructive Surgery, Center for Transgender and Gender Expansive Health, The Johns Hopkins University School of Medicine , Baltimore, MD,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3803-1537","authenticated-orcid":false,"given":"Sowmya","family":"Sharma","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Johns Hopkins University School of Medicine , Baltimore, MD,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0984-4600","authenticated-orcid":false,"given":"Joanna M","family":"Melia","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Johns Hopkins University School of Medicine , Baltimore, MD,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,12,16]]},"reference":[{"key":"2026040214063202800_izaf266-B1","author":"Herman","year":"2022"},{"key":"2026040214063202800_izaf266-B2","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1053\/j.gastro.2023.07.011","article-title":"Research considerations in digestive and liver disease in transgender and gender-diverse populations","volume":"165","author":"Newman","year":"2023","journal-title":"Gastroenterology"},{"key":"2026040214063202800_izaf266-B3","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.15585\/mmwr.mm6542a3","article-title":"Prevalence of inflammatory bowel disease among adults aged \u226518 years\u2014United States, 2015","volume":"65","author":"Dahlhamer","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026040214063202800_izaf266-B4","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1093\/ibd\/izae236","article-title":"The impact of hormone therapy on inflammatory bowel disease in transgender and nonbinary individuals","volume":"31","author":"Hassan","year":"2025","journal-title":"Inflamm Bowel Dis"},{"key":"2026040214063202800_izaf266-B5","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000003543","article-title":"Gender-affirming hormone therapy and risk of inflammatory bowel disease flare in transgender and gender diverse adults","author":"Bennett","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"2026040214063202800_izaf266-B6","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1111\/j.1572-0241.2007.01700.x","article-title":"Hormonal replacement therapy after menopause is protective of disease activity in women with inflammatory bowel disease","volume":"103","author":"Kane","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"2026040214063202800_izaf266-B7","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/1751-2980.12247","article-title":"Menstrual cycle, sex hormones in female inflammatory bowel disease patients with and without surgery","volume":"16","author":"Bharadwaj","year":"2015","journal-title":"J Dig Dis"},{"key":"2026040214063202800_izaf266-B8","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3390\/jpm13020165","article-title":"Impact of female gender in inflammatory bowel diseases: a narrative review","volume":"13","author":"Lungaro","year":"2023","journal-title":"J Pers Med"},{"key":"2026040214063202800_izaf266-B9","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1097\/MIB.0000000000000134","article-title":"The impact of hormonal contraception on disease-related cyclical symptoms in women with inflammatory bowel diseases","volume":"20","author":"Gawron","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"2026040214063202800_izaf266-B10","doi-asserted-by":"publisher","first-page":"116681","DOI":"10.1016\/j.socscimed.2024.116681","article-title":"\u201cNot just rebellious, it\u2019s revolutionary\u201d: do-it-yourself hormone replacement therapy as liberatory harm reduction","volume":"345","author":"August-Rae","year":"2024","journal-title":"Soc Sci Med"},{"key":"2026040214063202800_izaf266-B11","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1007\/s11606-018-4450-6","article-title":"Measuring the health of an invisible population: lessons from the Colorado transgender health survey","volume":"33","author":"Christian","year":"2018","journal-title":"J Gen Intern Med"},{"key":"2026040214063202800_izaf266-B12","doi-asserted-by":"publisher","first-page":"e2015036","DOI":"10.1001\/jamanetworkopen.2020.15036","article-title":"Assessment of health conditions and health service use among transgender patients in Canada","volume":"3","author":"Abramovich","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2026040214063202800_izaf266-B13","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1370\/afm.2586","article-title":"Insurance coverage and use of hormones among transgender respondents to a national survey","volume":"18","author":"Stroumsa","year":"2020","journal-title":"Ann Fam Med"},{"key":"2026040214063202800_izaf266-B14","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1097\/MLR.0000000000001693","article-title":"Prevalence of private and public health insurance among transgender and gender diverse adults","volume":"60","author":"Downing","year":"2022","journal-title":"Med Care"},{"key":"2026040214063202800_izaf266-B15","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S2213-8587(21)00185-6","article-title":"Mortality trends over five decades in adult transgender people receiving hormone treatment: a report from the Amsterdam cohort of gender dysphoria","volume":"9","author":"de Blok","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026040214063202800_izaf266-B16","doi-asserted-by":"publisher","first-page":"e2253687","DOI":"10.1001\/jamanetworkopen.2022.53687","article-title":"Analysis of mortality among transgender and gender diverse adults in England","volume":"6","author":"Jackson","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2026040214063202800_izaf266-B17","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1215\/00703370-9942002","article-title":"Differences in all-cause mortality among transgender and non-transgender people enrolled in private insurance","volume":"59","author":"Hughes","year":"2022","journal-title":"Demography"},{"key":"2026040214063202800_izaf266-B18","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1053\/j.gastro.2022.11.048","article-title":"A systematic review of inflammatory bowel disease epidemiology and health outcomes in sexual and gender minority individuals","volume":"164","author":"Newman","year":"2023","journal-title":"Gastroenterology"},{"key":"2026040214063202800_izaf266-B19","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1002\/ibd.20864","article-title":"Impact of perceived stigma on inflammatory bowel disease patient outcomes","volume":"15","author":"Taft","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"2026040214063202800_izaf266-B20","doi-asserted-by":"publisher","first-page":"e220978","DOI":"10.1001\/jamanetworkopen.2022.0978","article-title":"Mental Health outcomes in transgender and nonbinary youths receiving gender-affirming care","volume":"5","author":"Tordoff","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2026040214063202800_izaf266-B21","first-page":"23","article-title":"Gender-affirming care for transgender patients","volume":"19","author":"Bhatt","year":"2022","journal-title":"Innov Clin Neurosci"},{"key":"2026040214063202800_izaf266-B22","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1097\/SAP.0000000000003233","article-title":"Long-term outcomes after gender-affirming surgery: 40-year follow-up study","volume":"89","author":"Park","year":"2022","journal-title":"Ann Plast Surg"},{"key":"2026040214063202800_izaf266-B23","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1111\/apt.16647","article-title":"Use of contraceptives and risk of inflammatory bowel disease: a nested case-control study","volume":"55","author":"Pasvol","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"2026040214063202800_izaf266-B24","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s40264-015-0372-y","article-title":"Risk of inflammatory bowel disease with oral contraceptives and menopausal hormone therapy: current evidence and future directions","volume":"39","author":"Khalili","year":"2016","journal-title":"Drug Saf"},{"key":"2026040214063202800_izaf266-B25","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1097\/MEG.0000000000000915","article-title":"Exposure to oral contraceptives increases the risk for development of inflammatory bowel disease: a meta-analysis of case-controlled and cohort studies","volume":"29","author":"Ortizo","year":"2017","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2026040214063202800_izaf266-B26","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1515\/hmbci-2015-0014","article-title":"Testosterone therapy in men with Crohn\u2019s disease improves the clinical course of the disease: data from long-term observational registry study","volume":"22","author":"Nasser","year":"2015","journal-title":"Horm Mol Biol Clin Investig"},{"key":"2026040214063202800_izaf266-B27","doi-asserted-by":"publisher","first-page":"909","DOI":"10.3390\/cancers14040909","article-title":"The impact of estrogens and their receptors on immunity and inflammation during infection","volume":"14","author":"Harding","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2026040214063202800_izaf266-B28","doi-asserted-by":"publisher","first-page":"3313","DOI":"10.1210\/jc.2003-031069","article-title":"The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men","volume":"89","author":"Malkin","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"2026040214063202800_izaf266-B29","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.cyto.2015.01.007","article-title":"Estrogen alters baseline and inflammatory-induced cytokine levels independent from hypothalamic-pituitary-adrenal axis activity","volume":"72","author":"Shivers","year":"2015","journal-title":"Cytokine"},{"key":"2026040214063202800_izaf266-B30","doi-asserted-by":"publisher","first-page":"40443","DOI":"10.18632\/oncotarget.6217","article-title":"Linking estrogen receptor \u03b2 expression with inflammatory bowel disease activity","volume":"6","author":"Pierdominici","year":"2015","journal-title":"Oncotarget"},{"key":"2026040214063202800_izaf266-B31","doi-asserted-by":"publisher","first-page":"877","DOI":"10.21037\/tau.2016.09.04","article-title":"Hormone therapy for transgender patients","volume":"5","author":"Unger","year":"2016","journal-title":"Transl Androl Urol"},{"key":"2026040214063202800_izaf266-B32","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1089\/trgh.2021.0041","article-title":"Trends in feminizing hormone therapy for transgender patients, 2006-2017","volume":"8","author":"Rose","year":"2023","journal-title":"Transgend Health"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/32\/4\/643\/65923701\/izaf266.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/32\/4\/643\/65923701\/izaf266.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T18:06:37Z","timestamp":1775153197000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/32\/4\/643\/8381473"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,16]]},"references-count":32,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,12,16]]},"published-print":{"date-parts":[[2026,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izaf266","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2025,12,16]]}}}